Table 4.

Efficacy of BJOE injection in treating malignant pleural effusion

Study	Study design (N)		Pleural perfusion (N)		Efficacy of therapy									Improvement of SI (N,%)
			Group 1	Group 2	Group 1					Group 2
	Group 1	Group 2			CR	PR	SD	PD		CR	PR	SD	PD	Group 1	Group 2
Guo Y 2004 [13]	30	30	BJOE + P	P	11	15	4	0		5	11	14	0	–	–
Lei H 2006 [14]	31	30	BJOE + P	P	11	14	6	0		5	10	15	0	24(77.4)	12(40)
Wang H 2007 [15]	35	35	BJOE + P	P	13	16	6	0		7	13	15	0	32(91.4)	20(57.1)
Wu S 2009 [16]	68	55	BJOE + P	P	39	20	9	0		16	28	11	0	–	–
Fu X 2009 [17]	60	60	BJOE + P	P	22	28	8	2		14	21	18	7	44(73.3)	33(55)
Chen Y 2011 [18]	31	30	BJOE + P	P	12	13	6	0		8	9	13	0	–	–
Jia L 2011 [19]	35	35	BJOE+ L-OHP	L-OHP	10	18	7	0		8	15	12	0	–	–
Liu B 2012 [20]	32	32	BJOE + P	P	18	7	4	3		13	4	9	6	28(75)	24(50)
Zhang J 2012 [21]	28	36	BJOE + BLM	BLM	10	16	2	0		9	17	10	0	25(89.3)	21(58.3)
Zhang H 2013 [22]	34	30	BJOE + P	P	19	10	5	0		11	6	13	0	–	–
Yang G 2014 [23]	48	46	BJOE + P	P	14	26	8	0		4	22	16	4	42(87.5)	24(52.17)
Yang H 2014 [24]	32	32	BJOE + P	P	18	7	4	3		13	4	9	6	–	–
Yue K 2016 [25]	60	50	BJOE + P	P	23	27	10	0		13	14	23	0	43(71.7)	18(36)
Wang C 2016 [26]	30	30	BJOE + P	P	10	14	5	1		8	11	7	4	24(80)	16(53.3)

N cases; Group 1 BJOE combined with chemotherapeutic agents; Group 2 Chemotherapeutic agents alone, BJOE Brucea javanica oil emulsion; P cisplatin, L-OHP Oxaliplatin, BLM bleomycin, CR complete response, PR partial response, SD stable disease, PD progressive disease